

Eli Lilly and Company  
**Visiting Scientist Fellowship  
2023-2024**



## TABLE OF CONTENTS

The Visiting Scientist Fellowship . . . . .	<b>3</b>	Health Outcomes . . . . .	<b>11</b>
Visiting Scientist Concentrations . . . . .	<b>4</b>	Value, Evidence and Outcomes - U.S. Customer Engagement/Outcomes Liaisons . . . . .	11
About Eli Lilly and Company . . . . .	<b>5</b>	Value, Evidence and Outcomes - Early Phase Neuroscience . . . . .	11
Current Visiting Scientist Fellows . . . . .	<b>6</b>	Value, Evidence and Outcomes- Early Phase Immunology . . . . .	11
2023-2024 VSF Requirements, Application Process and Fellowship . . . . .	<b>7</b>	Medical Affairs . . . . .	<b>12</b>
Commercial . . . . .	<b>8</b>	Global Medical Omnichannel Capabilities . . . . .	12
Global Public Policy . . . . .	8	Global Medical Affairs - External Clinical Research . . . . .	12
Global Pricing, Reimbursement and Access: New Product Planning . . . . .	8	Global Medical Information . . . . .	12
Lilly Value and Access – Business Development . . . . .	9	Global & U.S. Medical Affairs . . . . .	13
Oncology New Product Planning . . . . .	9	Clinical Research Scientist: Global Diabetes. . . . .	13
Digital Health Product Strategy . . . . .	9	Regulatory Affairs . . . . .	<b>14</b>
Clinical Development and Project Management . . . . .	<b>10</b>	Global Labeling Department . . . . .	14
Clinical Development Design Hub. . . . .	10	Regulatory Strategy: North America . . . . .	14
Clinical Trial Project Management . . . . .	10	U.S. and International Policy and Intelligence . . . . .	14
Pharmaceutical Project Management . . . . .	10		
Clinical Trial Design & Data Insights . . . . .	10		



## THE VISITING SCIENTIST FELLOWSHIP

This is a highly respected pharmaceutical industry-based program, which has developed competitive and marketable industry professionals since 1994. A deeply involved, influential and passionate network of more than 200 alumni across the pharmaceutical industry are contributing to the development of the next generation of medicines to improve patient lives. Designed to train professionals for a career in the pharmaceutical industry, the fellowship offers a wide array of dynamic and challenging positions, while creating an environment that fosters personal and professional development. This one-year post graduate program presents Pharm.D., M.D., D.O. and relevant Ph.D. or Master's degree graduates with cross-functional exposure to **commercial, clinical development and project management, health outcomes, medical affairs and regulatory affairs** aspects of drug development. Fellows **directly impact** the business at Eli Lilly and Company to speed innovation while developing valuable and lifelong career skills.



*Visiting Scientist Fellowship Class of 2022-2023*



“ For nearly three decades, the Visiting Scientist Fellowship has been instrumental in launching the careers of top-talent pharmaceutical professionals. We’re proud of the enormous impact our VSF alumni have had across the industry in advancing the next wave of innovation to improve patient lives. ”

**David Riggs, Pharm.D.**

VSF 2000-2001

Associate VP-Global Regulatory Affairs

VSF Executive Sponsor

## VISITING SCIENTIST CONCENTRATIONS

Visiting Scientist Fellows have found successful and rewarding careers in a multitude of functional areas across pharmaceutical drug development and commercialization. Traditionally, the fellowship recruits within five core functions: commercial, clinical development and project management, health outcomes, medical affairs and regulatory affairs.

To learn more about Lilly and the fellowship program please visit <https://careers.lilly.com/visiting-scientist> and register to attend our webinar series:

- » Webinars led by fellows and leadership are scheduled for the following days and times:
  - Leadership session discussing the application & interview process: **Thursday, September 1 at 7:00 PM EDT.**
  - Fellow session discussing various positions & fellowship experience: **Thursday, September 13 at 7:00 PM EDT.**

### Commercial

The Commercial fellows merge clinical skills with business acumen and economics. This role requires vision and execution of best-in-class methodologies for the rapidly changing customer landscape. Fellows will provide knowledge and experience on customer insights, optimization of clinical trial design, pricing and access, contracting/distribution strategies, development of policy positions and product selection strategy and tactics.

### Clinical Development and Project Management

Clinical Development fellows work cross-functionally in the planning of clinical programs through use of rich data sources, targeted innovation and expertise in functional trial delivery. Fellows work across therapeutic areas to optimize study designs by connecting asset teams to new capabilities to improve patient/site experience, trial achievability and overall business processes.

Project Management fellows lead cross-functional teams by maintaining a clear focus on the overall scope, budget and timeline of a project in order to deliver high quality products. Within the pharmaceutical industry this occurs by translating a clinical development strategy into the creation and execution of a credible non-clinical and clinical project plan. Fellows are encouraged to gather a deep comprehension of the drug development process through proactive leadership and relationship building.

### Health Outcomes

The Health Outcomes fellows are part of our Value, Evidence and Outcomes (VEO) team and support the development and launch of important new medicines through cross-functional collaboration and real-world evidence generation. The purpose of the VEO team is to accelerate equitable patient access and transform healthcare delivery through the execution and communication of bold, high impact science. Fellows work in partnership with cross-functional teams (such as clinical development, marketing, commercial, scientific communications, regulatory and medical affairs) and provide strategic insight/leadership into the health economics and outcomes research (HEOR) needs (e.g., health economics, patient reported outcomes, real world evidence, access and reimbursement).

### Medical Affairs

Medical Affairs fellows support the launch of important new medicines through cross-functional collaboration and evidence generation. Fellows work in partnership with clinical development, marketing, patient safety, medical information, scientific communications, regulatory and advocacy to support the creation, development, approval and execution of clinical development and disease state support materials related to Lilly products in development and on the market. Fellows also have the opportunity to collect and analyze customer insights and generate evidence to support launch and post-launch deliverables.


### Regulatory Affairs

Regulatory Affairs fellows directly impact pharmaceutical product labeling, policy and intelligence initiatives, or advertising and promotion regulatory functions. Projects may encompass development and maintenance of core product labeling, assessment of promotional materials, partnering with global regulators for efficient regulatory requirements and/or engagement with trade organizations for policy initiatives. Regulatory affairs is involved in every stage of commercialization. Fellows will have the opportunity to understand and influence regulatory strategy for products in all phases of development and regulatory science initiatives globally.

## Visiting Scientist Leadership




**Jason Singer, Pharm.D.**  
VSF 2003-2004  
Associate Director,  
Global Medical Information,  
Oncology/Immunology  
*Program Coordinator*




**John J. Kaiser, Pharm.D.**  
VSF 2011-2012  
Senior Director,  
Global Regulatory Affairs,  
North America



**India Terrell, Pharm.D., MBA**  
VSF 2018-2019  
Associate Director,  
Global Brand Marketing,  
Neuroscience



**Ian Dilley, Pharm.D.**  
VSF 2018-2019  
Associate Director,  
Clinical Services,  
Supplies & Capabilities



**Theresa Hunter Gible, Ph.D., MPH, M.S.**  
VSF 2015-2016  
Senior Advisor,  
Value, Evidence and  
Outcomes, Research

## ABOUT ELI LILLY AND COMPANY


Eli Lilly and Company is one of the largest global, research-based pharmaceutical companies in the world. Lilly is committed to making medicines that help people live longer, healthier, more active lives.

Focused on the **core therapeutic areas of diabetes, immunology, oncology, neuroscience and pain**, approximately 37,000 employees keep patients and health care providers at the heart of every aspect of their business. Marketing products in 120 countries, Lilly strives to develop innovative medicines at lower costs and faster speeds.

Headquartered in Indianapolis, Indiana, Lilly provides a diverse and inclusive work environment. The company offers a variety of activities and employee resource groups for employees with common interests or similar experiences. Lilly is honored to be consistently ranked as one of the best companies to work for in the world and was recently recognized by DiversityInc as one of the top 5 most diverse and inclusive companies. Generations of Lilly employees have sustained a culture that values **excellence, integrity and respect for people**.




## CURRENT VISITING SCIENTIST FELLOWS




**Amy Lam, Pharm.D.**  
*Regulatory U.S. Advertising & Promotion*  
University of Southern California




**Antonieta Salguero, Ph.D.**  
*Novel Tech Modalities/Ventures*  
Johns Hopkins University  
Chemical Biology




**Arashpreet Kaur, Pharm.D.**  
*Global Scientific Communications*  
University of Illinois at Chicago  
College of Pharmacy



**Benjamin Behrend, Pharm.D.**  
*Value, Evidence, & Outcomes -*  
*Center of Innovation*  
St. John's University



**Bomina Park, Ph.D.**  
*Medical Affairs Clinical Research Scientist -*  
*Immunology*  
Indiana University  
Pharmacology and Toxicology



**Crystal Nnaji, Pharm.D.**  
*Clinical Services, Supplies*  
*and Capabilities*  
Purdue University



**Ellie Todd, Pharm.D.**  
*Regulatory Strategy*  
Purdue University



**Erica Rowane Bautista, Pharm.D., MCR**  
*Value, Evidence, & Outcomes -*  
*Outcomes Liaison*  
The Ohio State University



**Hussein Safaoui, Pharm.D.**  
*Pharmaceutical Project Management*  
Wayne State University



**Ike Emesih, Pharm.D.**  
*Global Pricing, Reimbursement and Access:*  
*New Product Planning*  
Texas Tech University Health  
Sciences Center



**Krystal Roggerson, Ph.D.**  
*Clinical Trial Project Manager*  
Morehouse School of Medicine  
Vascular Physiology




**MacKenzie Challoner, Pharm.D., MBA**  
*Omnichannel Capabilities &*  
*Medical Affairs Education*  
Drake University



**Megan Kirkpatrick, Pharm.D.**  
*Lilly U.S. Value and Access -*  
*Value Excellence*  
The Ohio State University



**Moises Rodriguez, Pharm.D.**  
*Global Medical Information*  
Midwestern University  
College of Pharmacy



**Nadia Ahmed, Pharm.D.**  
*Global Labeling Department (GoLD)*  
Howard University College of Pharmacy



**Olivia Geneus, Ph.D.**  
*Clinical Development Design Hub*  
University at Buffalo  
Chemistry



**Rehan Qureshi, Pharm.D., MBA**  
*Global Public Policy*  
Butler University



**Shea McMurtry, Ph.D.**  
*Medical Affairs Clinical Research*  
*Scientist - Oncology*  
Georgia Institute of Technology  
Neurophysiology

## 2023-2024 VSF REQUIREMENTS, APPLICATION PROCESS AND FELLOWSHIP

### Application Process

Acceptance into the Visiting Scientist Fellowship (VSF) is highly competitive. In addition to outstanding scholastic achievements, qualified candidates must have demonstrated exceptional communication and leadership capabilities.

### Minimum Requirements

The program requires a Pharm.D., M.D., or relevant Ph.D. or Master's degree completed by June 2023, but not before 2020. Qualified candidates must be legally authorized to be employed in the United States at the time of application.

Visit <https://careers.lilly.com/visiting-scientist> to find the most up-to-date information regarding the program, positions offered and to register for a webinar session.

**Additional questions:** Contact the leadership team at [VSF@lilly.com](mailto:VSF@lilly.com).

### Application Checklist

- Answer all questions and submit a "Request a Screening Interview" form (will be available on [VSF website](#) by **mid-September**).
- Submit CV/resume as a PDF with the form.
- Qualified candidates will be contacted via email to schedule a screening interview and will receive directions for submitting a formal application.

### Application and Interview Timeline

#### Mid to Late September

- » Request a screening interview by uploading a PDF version of your CV/resume and responding to the questions within the screening interview form.

#### September to October

- » Qualified candidates will receive an email with an invitation to submit a formal application and schedule a screening (first-round) interview.

#### October

- » The screening process includes up to two virtual events, including one 30-minute interview in Microsoft Teams (for the overall fellowship, not department-specific) and an invitation-only reception in our virtual Lilly platform via Zoom.

#### Mid to Late November

- » Top candidates from the screening process will be invited and provided directions to participate in on-site, second-round interviews in mid to late November consisting of 3-5 department-specific interviews based on their application preferences.
- » A 20-25-minute presentation with 5-10 minutes for Q&A on a topic of their choosing will be required from each candidate.

#### December

- » Final selection process concludes, with offers being extended.

#### June–July 2023

- » The 2023-2024 Visiting Scientist Fellowship will begin.



## COMMERCIAL



### Global Public Policy

Global Public Policy (GPP) provides strategic analysis, expert insights and practical recommendations on healthcare policy issues affecting Lilly and key stakeholders. GPP focuses on domestic and global policies affecting healthcare coverage, access, reimbursement, affordability and advancement.

#### The Visiting Scientist Fellow will

- » Develop well-reasoned issue assessments, policy landscape evaluation and position development through research, analysis and collaboration to help Lilly shape the public policy environment and support improved outcomes and incentives for investment in biopharmaceutical innovation.
- » Apply scientific knowledge and work cross functionally to develop and support policy recommendations, which could be used to advance Lilly priorities with policy makers.
- » Focus on today's important policy issues such as drug pricing, healthcare reform, biologics and biosimilars, health financing, benefits design and innovation policy through both a U.S. and global lens.

### Global Pricing, Reimbursement and Access: New Product Planning

Pricing, Reimbursement and Access New Product Planning (PRA NPP) is part of Lilly Value and Access and is responsible for influencing the development of pipeline medicines to reflect critical payer needs identified through payer feedback. The team also provides price and access recommendations for forecasts to support key business decisions with the goal of ensuring patients can access Lilly medicines and deliver strong business results. The focus is on the U.S., Japan and major European markets.

#### The Visiting Scientist Fellow will

- » Work across therapeutic areas in the pipeline to apply scientific expertise in a commercial role.
- » Work with the Global Public Policy fellow to deliver an environmental review of key markets and identify key opportunities/threats pertaining to pricing and market access.
- » Participate in market research and advisory boards to understand payers' needs and develop reports that outline key takeaways and implications.
- » Work on strategic projects based on business need and support the team in the development of price and access recommendations.



"The Visiting Scientist Fellowship program provided the platform from which my career was able to takeoff. Working and learning under the tutelage of Rob Holmes in Global Pricing, Reimbursement and Access, I not only gained foundational payer knowledge, but I was also able to build a strong network that I routinely leverage in my current role."

#### **Mnwabisi Mbangata, Pharm.D.**

Associate Director, U.S. Payer Marketing – Diabetes  
2018-2019 Visiting Scientist Fellow



## COMMERCIAL (CONTINUED)

### Lilly Value and Access – Business Development

The Lilly Value and Access organization is responsible for ensuring patient access to Lilly’s portfolio of medications across the United States. The Business Development team focuses on the deal development, governance approvals and contracting efforts needed to ensure Lilly’s products gain and maintain market access across Commercial, Part D, Medicaid and Group Purchasing Organization (GPO) segments.

#### The Visiting Scientist Fellow will

- » Develop deep knowledge of payer customers and the U.S. healthcare environment in which they operate.
- » Work cross-functionally with account, brand, legal, health outcomes, policy and market research teams in order to understand customer requests and internal stakeholder needs.
- » Use analytical skills to combine market research intel, forecasting and account and brand team insights into succinct business cases analyzing formulary access opportunities/threats.
- » Provide payer contracting support for payer customers to ensure appropriate formulary access to Lilly’s marketed product portfolio.

### Oncology New Product Planning

New Product Planning is responsible for championing the voice of the customer and is accountable for commercial activities and deliverables in support of the Oncology early development pipeline. They provide commercial leadership and guidance to global development teams by developing and applying an understanding of both current and future marketplace value drivers in order to shape the clinical development and commercial strategy of Lilly’s portfolio.

#### The Visiting Scientist Fellow will

- » Apply scientific/clinical expertise to assess the market strengths/weaknesses/opportunities/threats (SWOT) for specific research targets and compounds.
- » Collaborate with peers from research/early phase drug development, Market Research, Global Pricing, Reimbursement and Access (PRA), Value, Evidence and Outcomes (VEO), Forecasting and External Intelligence to ensure our strategies for development are robust and well informed.
- » Partner with Lilly affiliate team members worldwide to conduct cross-functional compound reviews, to ensure successful global registration and commercial strategies.



### Digital Health Product Strategy

The Digital Health organization partners across the entire drug product and customer engagement lifecycle, from R&D to clinical trials to drug product launch to in-market support for improved adherence and outcomes. Whether collaborating to solve brand-identified needs or innovating unique solutions intended for cross-therapeutic use, our team offers solution-oriented advice, digital expertise and innovative solutions. We aim to address some of Lilly’s biggest challenges through the innovation of connected trials and the use of technology to connect with patients who rely on our medicines.

#### The Visiting Scientist Fellow will

- » In collaboration with brands and cross-functional teams, understand patient needs and in-market experiences with digital solutions through a defined measurement plan.
- » Evaluate insights and develop recommendations for new innovations and/or features that could support improved patient engagement and better outcomes on our medications.
- » Develop approach for commercial embodiment of recommendations including in-market testing, clinical relevance testing (as required) and driving features through cross-functional stakeholder team alignment.
- » Grow in understanding of patient-centered, digital health solutions and how to apply these effectively in a manner that meets patient needs as well as appropriate medical, regulatory and legal expectations.



“The Visiting Scientist program provided to me an opportunity to continue to learn, be challenged and understand the career opportunities available within the pharmaceutical industry. During my year as a Visiting Scientist in U.S. Medical Information I had the opportunity to contribute to the commercialization phase of several compounds, including answering questions from health care professionals about Lilly products and conducting medical call center training. Additionally, I had the opportunity to expand my knowledge of the drug development process through coordinating and teaching the Butler University Drug Development Course and establishing a robust network within Lilly that I still utilize today, over twenty years later.”

#### Kristine Healey, Pharm.D.

Associate VP, COO, Medical Affairs Launch Readiness – Neuroscience  
2000-2001 Visiting Scientist Fellow

## CLINICAL DEVELOPMENT AND PROJECT MANAGEMENT



### Clinical Development Design Hub

The Design Hub is a multi-capability component of the Clinical Design, Delivery, & Analytics (CDDA) group consisting of therapeutically aligned teams. In partnership with Asset teams, the Design Hub creates innovative clinical trial design and delivery strategies with a focus on increasing efficiencies, speeding drug development and providing the best experience for health care providers and patients.

#### The Visiting Scientist Fellow will

- » Be incorporated into one of the TA teams, complete training, receive a peer coach(s) and assigned a project to lead.
- » Learn how clinical trial design enables effective delivery of trial outcomes.
- » Contribute to the development of optimized design and delivery elements in clinical plans that result in high quality and efficient clinical development outcomes. This may include: scientific, clinical and therapeutic expertise to inform trial design options; innovative design elements (e.g. decentralized clinical trials); utilizing analytics to inform clinical trial design and strategy; and increasing diversity in clinical trials.
- » Participate in a cross-Design Hub (and/or cross-CDDA) initiative

### Clinical Trial Project Management

The Clinical Trial Project Manager (CTPM) leads the cross-functional study team in the development and execution of clinical trials and is accountable globally to deliver trial(s) on time with high quality and within scope and budget. The CTPM leverages project management, clinical trial process and scientific expertise to drive actions and coordinate efforts to achieve trial deliverables.

#### The Visiting Scientist Fellow will

- » Understand the roles and responsibilities of functions peripheral to the CTPM position in clinical development (data management, medical writing, supply planning, regulatory, etc.).
- » Collaborate with the study team to develop study-related documentation and gain hands on experience in clinical trial execution activities.
- » Create and manage trial timelines and budgets.

### Pharmaceutical Project Management

The Pharmaceutical Project Manager (PPM) provides proactive cross-functional leadership for drug development to translate and execute the strategy for delivering a medicine to patients.

#### The Visiting Scientist Fellow will

- » Serve as the central hub and integration point of the drug development core team, working closely with individuals from Clinical, Chemistry, Manufacturing & Control (CMC), Toxicology, ADME, Regulatory, Health Outcomes, Legal, Discovery and Marketing.
- » Impact the drug development strategy and execution through the project timeline, scope, budget and risk to enable decision making for senior leadership.
- » Develop and utilize necessary project management skills to facilitate delivery of team timelines throughout drug development on budget and within scope for a project(s) in Lilly's portfolio.

### Clinical Trial Design & Data Insights

The Design Hub and Clinical Trial Design & Data Insights drive collaboration and the planning of clinical programs/trials through the use of data and insights, targeted innovative capabilities and expertise in trial design and delivery.

#### The Visiting Scientist Fellow will

- » Gain exposure to Lilly's therapeutic areas and the clinical development process by working in partnership with asset teams and clinical capabilities to improve and optimize study design and feasibility.
- » Provide input into key strategic decisions for a clinical program/trial, which may include country and site allocation, trial accessibility, competitive landscape analysis, patient recruitment and retention, study training and targeted innovation.
- » Connect asset teams with new, innovative and data-driven clinical capabilities that can enhance trial feasibility, patient and site experience and overall business processes.



"The Visiting Scientist Fellowship has encouraged me to explore all facets of the drug development process and immediately delve into my role in the rapidly changing environment that surrounds new product launch. I am challenged on a daily basis to provide essential medical support and ascertain innovative solutions to customer needs in order

to bring new lifesaving therapies to patients across the globe.

In addition the fellowship provides an essential support and development network of current and past fellows."

#### Kyle Frantz, Pharm.D.

Sr. Director, Field Medical Scientific Strategy – Thoracic & GI Cancer  
2016-2017 Visiting Scientist Fellow

## HEALTH OUTCOMES

### Value, Evidence and Outcomes - U.S. Customer Engagement/Outcomes Liaisons

The U.S. Customer Engagement team is a critical part of the Value, Evidence and Outcomes (VEO) organization and is responsible for delivering clinical, economic, observational and value-based evidence to U.S. formulary decision makers. The team serves the medical needs of value-based decision-making customers (e.g. payers, health systems) across the U.S. and across all Lilly therapeutic areas and products.

#### The Visiting Scientist Fellow will

- » Serve as a liaison between field-based outcomes liaisons who call on value-based customers and our internal business partners. The VSF will ensure necessary evidence, resources and insights are flowing in both directions.
- » Interact with colleagues across VEO, Medical Affairs and Commercial (Brand, Payer) teams to optimize research generated and solutions delivered to address customer needs.
- » Leverage an understanding of the clinical and health outcomes data and evidence needed to support customer responses and interactions.
- » Assist in the development and implementation of new capabilities and resources for Outcomes Liaisons as part of the U.S. Customer Engagement strategy and transformation initiative.

### Value, Evidence and Outcomes - Early Phase Neuroscience

The purpose of the Value, Evidence and Outcomes (VEO) team is to accelerate equitable patient access and transform healthcare delivery through the execution and communication of bold, high impact science. The VEO research scientist will provide strategic insight/leadership into the health economics and outcomes research (HEOR) needs (e.g., health economics, patient reported outcomes, real world evidence, access and reimbursement) for Lilly's early phase neuroscience portfolio..

#### The Visiting Scientist Fellow will

- » Partner with VEO scientists to develop Clinical Outcomes Assessments, Real World Evidence and/or economic value strategies for priority products in early phase neuroscience.
- » Develop and articulate product value propositions, patient reported outcomes strategies, real world evidence generation and differentiation strategies using HEOR research.
- » Lead and execute HEOR early phase neuroscience research projects.




### Value, Evidence and Outcomes- Early Phase Immunology

The Value, Evidence and Outcomes (VEO) team supporting early phase immunology provides scientific expertise to develop and champion health economics and outcomes research (HEOR) evidence strategies supporting the foundation for value and patient measurement for immunologic disease states. The VEO early phase immunology team collaborates cross-functionally as experts in HEOR and application of evidence to build a compelling value package for payers, healthcare practitioners, patients, caregivers and regulatory.

#### The Visiting Scientist Fellow will

- » Partner with VEO scientists to develop Clinical Outcomes Assessments, Real World Evidence and/or economic value strategies for priority products in early phase immunology.
- » Develop and update reports summarizing the burden of illness, epidemiology, cost and treatment patterns and associated value drivers for the various customers.
- » Develop communications and support transparency of information sharing across the early phase VEO immunology team and cross-functional business partners.
- » Lead and execute HEOR early phase immunology research projects.



“The Visiting Scientist Fellowship is an opportunity I have the pleasure to be a part of in my post-doctorate career. I have been entrusted to pioneer an innovative role within DSS that integrates Central Monitoring with the goal to further bridge together the ever evolving structure of the clinical trial study team. This allows for critical thinking, creativity and growth within the industry setting. The VSF leadership, past alumni, my supervisor, my coaches and my peers have all excelled at ensuring that I succeed at obtaining this goal.”

#### Nedina Kalezic, Pharm.D.

Associate Director, Value, Evidence and Outcomes - Outcomes Liaison  
2016-2017 Visiting Scientist Fellow

## MEDICAL AFFAIRS

### Global Medical Omnichannel Capabilities

The Medical Omnichannel Capabilities team, within the Global Medical Affairs office, partners cross-functionally with departments such as Global Medical Information, Global Medical Education, Global Scientific Communications and field-based medical professionals to enhance the Lilly customer experience for healthcare providers and to provide best-in-class digital services to customers.

#### The Visiting Scientist Fellow will

- » Be exposed to a variety of emerging medical digital technologies.
- » Gain insight into customer channel preferences and the medical digital landscape.
- » Innovate delivery of medical education and scientific evidence across digital channels through proof-of-concept and pilot projects.
- » Assist with exploration of novel types of medical content.
- » Develop business processes and enablement plans to scale new channels, content types, or capabilities.

### Global Medical Affairs - External Clinical Research

Scientific advancement in oncology occurs both through internal and external efforts. External Clinical Research & Operations (ECRO) organization at Lilly oversees all oncology external sponsored research (clinical, translational, diagnostic, collaborative and non-clinical). The ECRO organization is embedded in the drug development/lifecycle and external research is critical for the advancements in Oncology. Loxo@ Lilly oncology external research portfolio has grown by over 10x over the last several years. With these commitments, we need to understand how to measure the scientific return.

#### The Visiting Scientist Fellow will

- » Develop a framework to measure scientific return on investment for the external research portfolio (inputs, what and how to measure and work with team to incorporate into ECRO IT system).
- » Understand the Lilly ONC portfolio and external scope of work, committed portfolio and external process.
- » Learn about optimized integration of global external collaboration research programs as part of molecule development and lifecycle.
- » Assist in review of external submissions for decision making including concepts, proposals and protocol/protocol amendments.
- » Learn and apply communication, collaboration, problem-solving, self-management and prioritization skills.



### Global Medical Information

Global Medical Information (GMI) plays an integral role in driving medical launch strategy through creation of answers to unsolicited requests from customers (consumers, health care professionals and payers) and through collection and analysis of customer insights.

#### The Visiting Scientist Fellow will

- » Assist in the development and execution of medical information responses (standard medical responses, slide kits, literature searches, etc.) in support of a product launch, according to appropriate procedures.
- » Establish and maintain relationships within compound and cross-functional teams, across regions and geographies, to ensure quality responses designed to improve the customer experience.
- » Contribute to a multi-channel content strategy that delivers medical information to customers within their preferred channel.
- » Research and respond to unsolicited medical information inquiries from HCPs and consumers in a prompt, accurate and compliant manner.
- » Serve as the medical information expert in ongoing comprehensive product/disease area training to affiliate and call center partners.
- » Work collaboratively with Global Medical Affairs Office (GMAO) colleagues to execute content on lillymedical.com and monitor our medical social media channels.



## MEDICAL AFFAIRS (CONTINUED)

### Global & U.S. Medical Affairs

Global Medical Affairs is on a journey to optimize the strategic connection between what we discover in our Lilly Research Laboratories, how we develop those assets and how we engage customers with an omnichannel mindset. Medical Affairs is a subset of the broader medical organization, consisting of customer-facing functions that act across the lifecycle of a product and engage scientific experts, thought leaders, healthcare professionals, consumers and payers. Our value rests in informing our various customers about clinical trial portfolios, newly published data, outcomes-based information and new indications. Medical affairs is uniquely positioned to bring value to our customers.

#### The Visiting Scientist Fellow will

- » Gain exposure to Lilly’s neuroscience portfolio and Global/ U.S. Medical Affairs by working in partnership with colleagues from medical affairs functions and commercial teams including thought leader engagement, internal medical, strategy and operations and field-based medical.
- » Collaborate with cross-functional colleagues in Global Medical Affairs gaining hands-on experience spanning internal medical strategy work with a pull through to medical strategic solutions that include personal channels such as the Medical Science Liaison (MSL) role and non-personal channels such as digital outreach.
- » Connect with new and innovative capabilities and solutions that enhance the customer experience and improve patient outcomes.

### Clinical Research Scientist: Global Diabetes

The Diabetes Global Medical Affairs Clinical Research Scientist fellow will work with cross-functional business partners, field medical colleagues and the marketing team(s) to support the medical affairs strategy for new and currently marketed products. The fellow will be integrated as a fully contributing member of an internal medical affairs team to prepare for launch execution and support and/or support lifecycle management.

#### The Visiting Scientist Fellow will

- » Develop customer support materials, disease state educational materials, advisory board content to support interactions with external thought leaders, scientific conference materials to educate HCPs and other medical communication tools (e.g., scientific disclosures) in support of our products.
- » Provide medical expertise on disease state, product, and external environment to support execution of scientific and brand strategies. This includes review of promotional material to ensure scientific validity and appropriateness for the audience.
- » Routinely interface with internal partners to understand scientific (data disclosure plans, clinical development plans, etc.) and brand strategies.
- » Develop as a professional through mentorship, potential leadership opportunities and experience as an accountable individual (while a member of a team) in delivering tactics to achieve the medical affairs strategy.



“From starting new in the pharmaceutical industry and Medical Affairs, I was exposed to multiple areas of drug development and networked with leadership during my VSF year. I was able to create a space where my value is both recognized and embraced at Lilly. The harmonization of the VSF program and Lilly accelerated my growth by preserving its promise- to provide unique opportunities, an open culture, diverse mentors and lifetime friends.”

#### Carlos Diaz, Pharm.D.

Advisor, Global and U.S. Medical Affairs Clinical Research Scientist – Rheumatology  
2021-2022 Visiting Scientist Fellow

## REGULATORY AFFAIRS



### Global Labeling Department

The Global Labeling Department (GoLD) within Global Regulatory Affairs leads the development of labeling for drug and combination device products. GoLD is responsible for developing internal labeling used by Lilly affiliates around the world (Core labeling) in addition to labeling for the U.S. and Canada.

#### The Visiting Scientist Fellow will

- » Manage product labeling within a specific therapeutic area and collaborate with colleagues in Regulatory, cross-functional drug development teams and Lilly affiliates.
- » Lead updates to Core labeling, carton and container labels and instructions for use for products that are marketed in the U.S. and Canada.
- » Understand FDA and Health Canada regulations and guidance on drug and combination device labeling.

### Regulatory Strategy: North America

The Regulatory Strategy scientist in Global Regulatory Affairs develops regulatory strategies, leads regulatory risk assessments and influences drug development teams on the non-clinical and clinical requirements to achieve approval of marketing applications in the U.S. and Canada. The scientist also leads interactions with the U.S. Food & Drug Administration (FDA) and Health Canada (HC) to inform on drug development strategies to support strategic and compliance submissions.

#### The Visiting Scientist Fellow will

- » Understand FDA and HC laws, regulations and guidance related to the drug development process and requirements to obtain product approval
- » Assist in the development of regulatory strategies, communicate submission and approval requirements and regulator expectations and consult on regulatory issues and regulatory risks
- » Collaborate with other regulatory colleagues and internal partners such as research & development and drug development teams
- » Monitor upcoming and recent approvals of competitive development programs

### U.S. and International Policy and Intelligence

Global Regulatory Affairs (GRA) develops optimal regulatory strategies to deliver innovative medicine approvals for the patients we serve. GRA policy fosters policy changes that enable the regulatory environment to best accommodate innovative medicines. GRA policy staff engage with multiple Lilly functions and external regulatory stakeholders (e.g., FDA, EMA, NMPA, PhRMA, EFPIA and NHC) to advocate for constructive regulatory reforms.

#### The Visiting Scientist Fellow will

- » Assess the potential impact of external global regulatory trends on regulatory strategies and the company's portfolio.
- » Summarize, analyze, integrate, interpret and present information and intelligence to regulatory partners.
- » Develop Lilly's position on key regulatory policy issues and advocate for policy change in the U.S., Europe and other countries.
- » Cultivate opportunities to engage in external multi-stakeholder coalitions to achieve shared regulatory policy objectives.



"As a Visiting Scientist, I gained a broader understanding of key functions across the company as well as the biopharmaceutical industry in general. The program afforded me with opportunities to meet company leaders, enhance my technical acumen, explore career interests and to make lasting friendships — all of which are still integral to me today."

#### Mark Mayer, Pharm.D., MBA

Associate VP, Global Regulatory Policy and Intelligence  
2002-2003 Visiting Scientist Fellow



*Lilly*

2022 CA approved for external use. Printed in the USA.  
©2022, Eli Lilly and Company. ALL RIGHTS RESERVED.